BACKGROUND The long-term outcome of atrial fibrillation (AF) ablation demonstrates attrition. This outcome may be
A trial fibrillation (AF) affects w2.7 million people in the United States alone, and its prevalence is expected to rise to 15.9 million by 2050, with a significant impact on health care (1) (2) (3) .
Although population aging is regarded as an important contributor, several risk factors such as hypertension, diabetes mellitus (DM), obesity, and obstructive sleep apnea (OSA) have been linked as promoters of AF (4-7).
Catheter ablation of AF has evolved as an effective therapy for drug-refractory symptomatic AF (8).
Studies have demonstrated the advantage of catheter ablation over pharmacological methods of rhythm control (9-12). However, reports of long-term outcomes of AF ablation demonstrate attrition in success with time (13) (14) (15) (16) (17) . Studies have associated some cardiac risk factors with more frequent recurrence of AF (18) (19) (20) . We hypothesized that the attrition in the success of AF ablation is due to progression of the disease process that promoted the development of AF. The goal of the present study was to evaluate the impact of aggressive cardiac risk factors and weight management on outcomes of catheter ablation. W e i g h t m a n a g e m e n t . A structured motivational and goal-directed program using face-to-face counseling was used for weight reduction. Patients were encouraged to utilize support counseling and schedule more frequent reviews, as required. Initial weight reduction was attempted by using a meal L i p i d m a n a g e m e n t . Lipids were initially managed with lifestyle measures; if patients were unable to achieve low-density lipoprotein cholesterol levels <100 mg/dl after 3 months, use of a hydroxymethylglutaryl coenzyme A reductase inhibitor was then initiated. Fibrates were used for isolated hypertriglyceridemia (triglycerides >500 mg/dl) or added to statin therapy if triglyceride levels were >200 mg/dl and non-high-density lipoprotein cholesterol levels were >130 mg/dl. FOLLOW-UP. Physicians blinded to the patient's study group assessed patients for arrhythmia recurrence. Reviews were every 3 months for the first year
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Flow diagram of patient recruitment and attrition. Of 165 patients (69 in the risk factor
[RF] management group and 96 in the control group), 16 were excluded from the analysis due to lack of regular follow-up in 13 from other states (7 RF management and 6 control) or systemic illness in 3 (1 with malignancy and 2 with systemic inflammatory diseases).
AF ¼ atrial fibrillation; BMI ¼ body mass index.
Pathak et al.
Risk Factor Reduction and AF Ablation Baseline characteristics were similar in the 2 groups (Table 1) . Table 2 shows the impact of RFM on various cardiac risk factors. Values are mean AE SD or n. *The p value is for within-group differences (baseline to follow-up). †The p value is for between-group differences over time (group-time interaction). ‡Median follow-up: 42.8 months for the RFM group and 42.4 months for the control group.
RISK FACTOR MODIFICATION.
DM ¼ diabetes mellitus; HbA1c ¼ glycosylated hemoglobin; SBP ¼ systolic blood pressure; other abbreviations as in Table 1 . Pathak et al.
At baseline, 52% of RFM patients and 61% of control subjects had severe OSA (AHI $30; p ¼ 0.2). Of these, 16 (50%) RFM patients had an AHI <15, which we regarded as mild or no OSA when retested at follow-up, compared with 8 (15%) control subjects (p < 0.001).
Of patients requiring CPAP, compliance with CPAP use was significantly higher in RFM patients compared with control subjects (77% vs. 32%; p ¼ 0.001).
Most patients successfully stopped smoking: 19 (95%) RFM patients and 28 (90.3%) control subjects (p ¼ 0.5). In the RFM group, 9 (81.8%) patients successfully managed to reduce alcohol consumption to <30 g/week, whereas 15 (62.5%) control subjects achieved this goal (p ¼ 0.2).
ABLATION. Groups underwent ablation procedures at similar rates (RFM 1.6 AE 0.7 per patient; control Error bars indicate 95% confidence intervals. RFM ¼ risk factor management; other abbreviation as in Figure 1 .
Risk Factor Reduction and AF Ablation thickness decreased with RFM from 11.6 AE 1.7 mm to 9.6 AE 1.7 mm (p < 0.001) and in control subjects from 11.3 AE 1.6 mm to 10.9 AE 1.9 mm (p ¼ 0.04). There was a greater reduction in the RFM patients compared with the control subjects (p < 0.001).
ATRIAL FIBRILLATION. S y m p t o m b u r d e n . At baseline, both groups had comparable and high AFSS subscale scores ( Table 2 ). Figure 2 shows changes from baseline to final follow-up for the AFSS subscale pertaining to total AF burden and symptom severity.
AF frequency, duration, symptoms, and symptom severity were less at final follow-up in both groups, with a significantly greater reduction seen with the RFM group (p < 0.001). The global well-being score improved by >2-fold after ablation, with the RFM group improving from 2.4 AE 0.9 to 7.6 AE 1.7 (p < 0.001) and the control group improving from 2.5 AE 0.9 to 5.7 AE 2.0 (p < 0.001). However, improvement was markedly better with RFM patients than with control subjects (p < 0.001).
Single-procedure arrhythmia-free survival. Multiple interventions arrhythmia-free survival. procedures, which, in general, have occurred early (13, 14, 26) and are related to incomplete ablation during previous efforts with residual pulmonary vein conduction (27, 28) . More concerning is that, despite further ablation and a period without arrhythmia, progressive attrition in success is observed with time (13, 14, 18) . This late recurrence was proposed to also be due to persistent pulmonary vein conduction (27, 28) . However, it seems unusual that recovery of pulmonary vein conduction, which would be expected to occur early, would contribute to delayed recurrence of arrhythmia. Several single-center experiences identified a variety of cardiac risk factors that were more frequently present in patients with late recurrence of AF (19, 20, 29, 30) .
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